1. Home
  2. PAYX vs BIIB Comparison

PAYX vs BIIB Comparison

Compare PAYX & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paychex Inc.

PAYX

Paychex Inc.

HOLD

Current Price

$97.00

Market Cap

32.6B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$193.25

Market Cap

27.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAYX
BIIB
Founded
1979
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.6B
27.3B
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
PAYX
BIIB
Price
$97.00
$193.25
Analyst Decision
Hold
Buy
Analyst Count
16
25
Target Price
$111.67
$206.83
AVG Volume (30 Days)
2.9M
1.0M
Earning Date
03-25-2026
04-29-2026
Dividend Yield
4.59%
N/A
EPS Growth
N/A
N/A
EPS
3.71
2.15
Revenue
$5,571,700,000.00
$9,890,600,000.00
Revenue This Year
$19.19
N/A
Revenue Next Year
$5.50
N/A
P/E Ratio
$25.41
$88.14
Revenue Growth
5.56
2.22
52 Week Low
$85.45
$121.06
52 Week High
$161.24
$205.97

Technical Indicators

Market Signals
Indicator
PAYX
BIIB
Relative Strength Index (RSI) 60.99 53.78
Support Level $87.59 $170.52
Resistance Level $101.00 $204.19
Average True Range (ATR) 2.77 5.61
MACD 0.43 -0.64
Stochastic Oscillator 97.90 35.44

Price Performance

Historical Comparison
PAYX
BIIB

About PAYX Paychex Inc.

Paychex is a technology company providing human capital management solutions, enabling clients to better implement payroll, talent, time, tax, and benefits administration. It has a diverse set of product offerings addressing client needs. Aside from its traditional cloud-based payroll and HCM software offering, which accounts for close to half of total revenue, the company provides outsourcing options. Paychex's administrative service organization and professional employer organization accounts generate over 40% of sales. The balance of revenue is generated through retirement services, insurance solutions, and other products. In fiscal 2025, the company had 800,000 clients and almost 2.5 million worksite employees across its ASO and PEO.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: